Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers.

ABSTRACT:

Background and objective

Serous endometrial cancers (ECs) are an aggressive histotype of ECs which are disproportionately responsible for 40% of cancer-specific mortality rates despite constituting only 5-10% of all uterine cancers in incidence. In recent times, it has become increasingly evident that about 20-40% of uterine serous cancers (USCs) have molecular alterations in ERBB2 pathway with human epidermal growth factor receptor 2 (HER2/neu) amplification or overexpression. We summarise the evidence on genetic and molecular alterations in HER2/neu pathway in USC with a focus on testing criteria, targeting agents and resistance mechanisms.

Methods

We conducted a database search of PubMed/Medline up to 28th February 2023 for articles published in the English languag

SUBMITTER: Jayraj AS 

PROVIDER: S-EPMC11304437 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature